# Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

> **NCT01219907** · PHASE1 · WITHDRAWN · sponsor: **University of Washington**

## Conditions studied

- HER2-positive Breast Cancer
- Male Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** HER-2/neu peptide vaccine
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** ex vivo-expanded HER2-specific T cells
- **OTHER:** laboratory biomarker analysis
- **OTHER:** flow cytometry
- **OTHER:** immunoenzyme technique

## Key facts

- **NCT ID:** NCT01219907
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-06
- **Primary completion:** 2014-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01219907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01219907, "Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01219907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*